Add Feed
News Archives
2005
NanoMed Pharmaceuticals Founders Issued Patent for Use of Nanoparticles to Detect Radioisotopes
LEXINGTON, KY and KALAMAZOO, MI., (November 29, 2005) - NanoMed Pharmaceuticals, Inc. founders Michael Jay, Ph.D. and Russell J. Mumper, Ph.D. have been issued U.S. Patent 6,855,270 entitled "NanoScintillation Systems For Aqueous-Based Liquid Scintillation Counting." Their invention, assigned to the University of Kentucky Research Foundation and licensed exclusively to NanoMed Pharmaceuticals, covers processes to make nanoparticle-based NanoScintillation Systems which are used to detect beta-particle- or alpha-particle-emitting radioisotopes without the use of the organic solvents commonly used in conventional liquid scintillation (LS) "cocktails". Read More...
NanoMed Pharmaceuticals Receives Option to Exlusive License To Novel Product for Oral Cancer Chemoprevention
Phase I/Ia Study To Be Conducted at The Ohio State University's College of Dentistry and the James Cancer Hospital and Solove Research Institute
LEXINGTON, KY AND KALAMAZOO, MI (December 13, 2005) - NanoMed Pharmaceuticals, Inc. today announced that, under an Inter-institutional Agreement with The Ohio State University, the University of Kentucky Research Foundation has granted the company an option for an exclusive license to a novel Bioadhesive Berry Gel for the chemoprevention and treatment of oral epithelial dysplasia - the precancerous lesions that can develop into oral squamous cell carcinoma (SCC). Despite focused efforts to improve therapy, five-year survival rates for patients with advanced stage SCC remain discouragingly low. Of the estimated 30,000 newly diagnosed cases of oral cancer in the U.S. each year, only half of those diagnosed will be alive in 5 years. Worldwide the diagnoses of head and neck cancer are much greater, with over 350,000 to 400,000 new cases being found each year.
NanoMed Pharmaceuticals Founder Cited by National Nanotechnology Coordination Office
(November 17, 2006) NanoMed Pharmaceuticals Founder Cited by National Nanotechnology Coordination OfficeNanoparticles Referenced by NCI as Non-Toxic to Blood Cells
Common Nanoparticle Shown to Be Non-toxic to Blood Cells
(October 3, 2005) Though many kinds of nanoparticles, loaded with a variety of drugs and imaging agents, are making their way toward the clinic, questions about nanoparticle toxicity remain to be answered. Given that the majority of nanoparticles are intended to travel to tumors through the bloodstream, the effects of nanoparticles on blood cells are of particular concern to those developing nanoparticle-based therapeutic and imaging agents. Now, a series of experiments by researchers at the University of Kentucky have found no ill effects when blood cells are exposed to one common type of nanoparticle.
NanoMed Pharmaceuticals Founder Co-Develops Novel Gel for Oral Chmoprevention
(April 9, 2005) NanoMed Pharmaceuticals Founder Co-Develops Novel Gel for Oral ChmopreventionTestimony to the House Committee on Science
(November 17, 2005) Testimony to the House Committee on ScienceNew Vaccine Technologies Carry and Deliver
(May 2, 2005) New Vaccine Technologies Carry and Deliver
